List view / Grid view
Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…
An autonomous strategy for molecular discovery could enable the exploration of a far broader chemical space than is possible with conventional approaches. In this article, Niamh Morris from Rosalind Franklin Institute outlines why activity-directed synthesis (ADS) could be the answer, providing examples of how this technique has the potential to…
Dr Sheraz Gul examines how patient-driven imaging strategies can be utilised to aid the translation of initial research all the way into the clinic.
Using a natural language-inspired technique, researchers at the University of Central Florida, US, developed an interpretable and generalisable drug target interaction model that achieves 97 percent accuracy in identifying drug candidates for a broad variety of target proteins. Here, Dr Ozlem Ozmen Garibay and Aida Tayebi, who worked on the…
Today’s drug screening methods use one or two types of data. However, disease biology is not replicable by simple screening models because diseases are complex and heterogenous. However, advanced screening methods that process dozens of data sources at one time have uncovered novel hits that have been overlooked across the…
Despite decades without vaccine development in the respiratory syncytia virus (RSV) space, researchers are now homing in on a potential strategy to protect individuals from this disease. Here, Drug Target Review’s Ria Kakkad spoke with Dr Christy Comeaux, Medical Lead (RSV), Janssen, about the challenges associated with RSV vaccine development and her most promising…
Opioid addiction is an ongoing crisis in the US. Researchers have identified a key regulator that shapes analgesic and aversive outputs of kappa opioid receptor signalling, finding lead inhibitors of this previously ‘undruggable’ target class – the Regulators of G protein Signalling (RGS proteins) – to help re-establish non-addictive kappa…
This application note discusses why CAR T-cell therapy is so exciting, notes some common hurdles in development and manufacturing and proposes ddPCR technology as a solution for some of these issues.
Cytokine multiplex assays allow researchers to measure multiple cytokines, chemokines and growth factors from one small sample.
The tumour microenvironment can prevent some T cells from carrying out their immunotherapeutic duties. In this Q&A, Dr Brian Shy, Clinical Instructor at the University of California, San Francisco (UCSF) Department of Laboratory Medicine, describes a recent study wherein he and fellow scientists discovered a strategy to strengthen T cells…
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…
In this article, Bryan Oronsky, Chief Development Officer, and Tony Reid, Chief Executive Officer of EpicentRx, explain how AdAPT-001 uses tumour cells as a factory to make the TGF-beta trap that it carries. This trap neutralises the immunosuppressive protein, transforming growth factor–β to ‘heat up’ tumours and sensitise them to…
In this ebook are articles on immune checkpoint inhibitors and enhancing CAR T-cell therapies.
In this ebook are articles on how artificial intelligence can be used to identify drug candidates, data-lead screening models and autonomous strategies for molecular discovery.
